Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events). Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash
- Closing depends on the proposed Fulcrum-Slate merger, or necessary approvals if the merger terminates
- Sale proceeds expected in escrow before merger closing and credited to Fulcrum’s net cash
- Higher net cash expected to increase the cash dividend payable to Fulcrum stockholders
- Transaction adds merger-closing risk because asset-sale proceeds and resulting dividend depend on required conditions being satisfied
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.